Glen P Marszalowicz
Overview
Explore the profile of Glen P Marszalowicz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
183
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Magee M, Abraham T, Baybutt T, Flickinger Jr J, Ridge N, Marszalowicz G, et al.
Cancer Immunol Res
. 2018 Apr;
6(5):509-516.
PMID: 29615399
One major hurdle to the success of adoptive T-cell therapy is the identification of antigens that permit effective targeting of tumors in the absence of toxicities to essential organs. Previous...
2.
Magee M, Kraft C, Abraham T, Baybutt T, Marszalowicz G, Li P, et al.
Oncoimmunology
. 2016 Nov;
5(10):e1227897.
PMID: 27853651
Adoptive T-cell therapy (ACT) is an emerging paradigm in which T cells are genetically modified to target cancer-associated antigens and eradicate tumors. However, challenges treating epithelial cancers with ACT reflect...
3.
Marszalowicz G, Snook A, Magee M, Merlino D, Berman-Booty L, Waldman S
Oncotarget
. 2014 Oct;
5(19):9460-71.
PMID: 25294806
The emergence of targeted cancer therapy has been limited by the paucity of determinants which are tumor-specific and generally associated with disease, and have cell dynamics which effectively deploy cytotoxic...
4.
Gibbons A, Lin J, Kim G, Marszalowicz G, Li P, Stoecker B, et al.
Cancer Res
. 2013 Oct;
73(22):6654-66.
PMID: 24085786
Tumorigenesis is a multistep process that reflects intimate reciprocal interactions between epithelia and underlying stroma. However, tumor-initiating mechanisms coordinating transformation of both epithelial and stromal components are not defined. In...
5.
Magee M, Snook A, Marszalowicz G, Waldman S
Biomark Med
. 2013 Feb;
7(1):23-35.
PMID: 23387482
Throughout the last century medical advances in cancer treatment in the fields of surgery, radiation therapy and chemotherapy have greatly impacted patients' survival rates. Nevertheless, cancer remains a significant cause...
6.
Snook A, Magee M, Marszalowicz G, Schulz S, Waldman S
Cancer Immunol Immunother
. 2011 Nov;
61(5):713-23.
PMID: 22057677
Guanylyl cyclase C (GUCY2C) is the index cancer mucosa antigen, an emerging class of immunotherapeutic targets for the prevention of recurrent metastases originating in visceral epithelia. GUCY2C is an autoantigen...